TRDA
Entrada Therapeutics Inc
$
5.280
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.550
Open
5.390
VWAP
5.37
Vol
375.66K
Mkt Cap
200.84M
Low
5.225
Amount
2.02M
EV/EBITDA(TTM)
--
Total Shares
33.76M
EV
-147.85M
EV/OCF(TTM)
--
P/S(TTM)
2.84
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. It is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
6.85M
-66.67%
-0.978
+132.74%
8.12M
-78.29%
-1.020
-3500%
8.62M
-55.95%
-0.965
+175.71%
Estimates Revision
The market is revising No Change the revenue expectations for Entrada Therapeutics, Inc. (TRDA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -25.00%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-25.00%
In Past 3 Month
4 Analyst Rating
Wall Street analysts forecast TRDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRDA is 18.50 USD with a low forecast of 17.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.280
Low
17.00
Averages
18.50
High
20.00
Current: 5.280
Low
17.00
Averages
18.50
High
20.00
Goldman Sachs
Paul Choi
initiated
2025-09-17
Reason
Goldman Sachs
Paul Choi
Price Target
2025-09-17
initiated
Reason
Goldman Sachs analyst Paul Choi initiated coverage of Entrada Therapeutics with an Early-Stage Biotech designation, saying the company's Endosomal Escape Vehicle platform is differentiated from other delivery peptide approaches. It sees \"best-in-class potential.\"
Roth Capital
Buy
downgrade
$21 -> $17
2025-08-07
Reason
Roth Capital
Price Target
$21 -> $17
2025-08-07
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Entrada Therapeutics to $17 from $21 and keeps a Buy rating on the shares after meeting with its management to discuss the company's DMD clinical programs, particularly, ENTR-601-44 and ENTR-601-45. The company's robust cash position and multiple clinical data readouts anticipated in 2026 drive the firm's optimism, though Roth is also acknowledging the broader negative sentiment enshrouding the company's stock, partly fueled by a lack of value driving data catalyst events in 2025, the analyst tells investors in a research note.
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$23 -> $21
2025-05-12
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$23 -> $21
2025-05-12
downgrade
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Entrada Therapeutics to $21 from $23 and keeps a Buy rating on the shares after discussing the progress of the company's DMD clinical programs. The firm remains enthusiastic about ENTR-601-44 and ENTR-601-45, looking forward to the respective clinical trial starts in the U.S. and ex-U.S. regions, though also acknowledges the latter's clinical trajectory could be "long and winding", the analyst tells investors in a research note.
Roth Capital
Buy
downgrade
$23 -> $21
2025-05-11
Reason
Roth Capital
Price Target
$23 -> $21
2025-05-11
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Entrada Therapeutics to $21 from $23 and keeps a Buy rating on the shares. The firm remains "enthusiastic" about ENTR-601-44 and ENTR-601-45 following Entrada's Q1 report.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$20
2025-03-31
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$20
2025-03-31
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$20
2025-02-04
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$20
2025-02-04
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Entrada Therapeutics Inc (TRDA.O) is -1.32, compared to its 5-year average forward P/E of -16.69. For a more detailed relative valuation and DCF analysis to assess Entrada Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-16.69
Current PE
-1.32
Overvalued PE
37.59
Undervalued PE
-70.98
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.55
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.11
Undervalued EV/EBITDA
-7.20
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
6.43
Current PS
0.00
Overvalued PS
11.98
Undervalued PS
0.88
Financials
Annual
Quarterly
FY2025Q2
YoY :
-97.94%
1.95M
Total Revenue
FY2025Q2
YoY :
-187.69%
-46.85M
Operating Profit
FY2025Q2
YoY :
-178.32%
-43.10M
Net Income after Tax
FY2025Q2
YoY :
-167.10%
-1.04
EPS - Diluted
FY2025Q2
YoY :
-176.74%
-29.76M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
YoY :
+1960.03%
-159.24
FCF Margin - %
FY2025Q2
YoY :
-3903.84%
-2.21K
Net Margin - %
FY2025Q2
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
761.2K
USD
6
3-6
Months
1.4M
USD
6
6-9
Months
19.0K
USD
1
0-12
Months
2.9M
USD
16
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
761.2K
USD
6
3-6
Months
1.4M
USD
6
6-9
Months
19.0K
USD
1
0-12
Months
2.9M
USD
16
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TRDA News & Events
Events Timeline
2025-08-06 (ET)
2025-08-06
07:03:14
Entrada Therapeutics reports Q2 EPS ($1.04), consensus (86c)
2025-06-03 (ET)
2025-06-03
07:09:25
Entrada Therapeutics appoints Radhakrishnan to board of directors
2025-05-28 (ET)
2025-05-28
07:04:16
Entrada Therapeutics receives authorization from in EU to start ELEVATE-45-201
Sign Up For More Events
Sign Up For More Events
News
9.5
08-06NASDAQ.COMEntrada (TRDA) Q2 Revenue Drops 98%
4.0
07-01NASDAQ.COMValidea Kenneth Fisher Strategy Daily Upgrade Report - 7/1/2025
5.0
06-03NewsfilterEntrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Sign Up For More News
People Also Watch
VLGEA
Village Super Market Inc
37.670
USD
-2.61%
BHB
Bar Harbor Bankshares
31.530
USD
+1.25%
TWI
Titan International Inc
7.960
USD
-2.45%
BLDP
Ballard Power Systems Inc
2.880
USD
+5.11%
EGY
VAALCO Energy Inc
4.110
USD
-0.72%
UNTY
Unity Bancorp Inc
51.360
USD
-0.17%
UIS
Unisys Corp
4.100
USD
+1.99%
SNDL
SNDL Inc
2.470
USD
0.00%
KE
Kimball Electronics Inc
31.930
USD
+1.08%
NLOP
Net Lease Office Properties
29.490
USD
+1.48%
FAQ
What is Entrada Therapeutics Inc (TRDA) stock price today?
The current price of TRDA is 5.28 USD — it has decreased -2.58 % in the last trading day.
What is Entrada Therapeutics Inc (TRDA)'s business?
What is the price predicton of TRDA Stock?
What is Entrada Therapeutics Inc (TRDA)'s revenue for the last quarter?
What is Entrada Therapeutics Inc (TRDA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Entrada Therapeutics Inc (TRDA)'s fundamentals?
How many employees does Entrada Therapeutics Inc (TRDA). have?